Seasonal Affective Disorder Market Research Report - Global Forecast till 2027

Seasonal Affective Disorder Market information: by type (fall and winter SAD, and others), by diagnosis (physical exam, lab tests, and others), by treatment (light therapy, medications, and others), by end user- global forecast till 2027

ID: MRFR/Pharma/2779-HCR | February 2021 | Region: Global | 78 pages

Synopsis of Seasonal Affective Disorder Market


The seasonal affective disorder market is expected to grow at the CAGR of 4.2% during the forecast period and is estimated to reach USD 694.9 million by 2023. Seasonal Affective Disorder (SAD) is a type of depression that occurs during a certain time of the year. This disorder is related to changes in seasons, mostly occurs in winter but some people may have this disorder in summers as well. Seasonal affective disorder is most common in women, people between the ages of 15 to 55, and the people who live far from the equator where winter daylight hours are too short. Some major symptoms of this disorder are hopelessness, increased appetite, weight gain, loss of the ability to concentrate, social withdrawal etc. There are some risk factors associated with this disorder such as major depressive disorder, Bipolar I disorder, Bipolar II disorder, and others.


Increasing prevalence and growing awareness of this disorder are driving the seasonal affective disorder market growth. Increasing number of physician visits related to seasonal affective disorder is increasing which is another growth factor for the market. Some other factors such as changing lifestyle and lack of exercise are also key drivers for the market growth. Availability and adoption of new treatments for this disorder are another important factor for the market growth. The seasonal affective disorder market is growing moderately and is expected to continue its growth during the forecast period.


Segments        


The seasonal affective disorder market is segmented on the basis of type, which includes fall and winter SAD, spring and summer SAD, and others.


On the basis of diagnosis, the seasonal affective disorder market is segmented into physical exam, lab tests, psychological evaluation, and others. Lab tests is sub-segmented into complete blood count (CBC), thyroid blood tests, and others. Psychological evaluation includes intelligence tests, personality tests, attitude tests, achievement tests, aptitude tests, neuropsychological tests, vocational tests, direct observation tests, and others.


On the basis of treatments, the seasonal affective disorder market is segmented into light therapy (phototherapy), medications, psychotherapy, counselling, and others. Medications includes antidepressants, and others. Antidepressants is further sub-segmented into reuptake inhibitors (SSRIs), and others. Psychotherapy includes art therapy, attachment-based psychotherapy, behavioral therapy, body psychotherapy, Cognitive analytical therapy (CAT), existential psychotherapy, gestalt therapy, and others.


On the basis of end user, it is segmented into hospitals & clinics, academic institutes, medical research centers, and others.


FIGURE 1 GLOBAL SEASONAL AFFECTIVE DISORDER MARKET SHARE BY END USER, 2016 (%) SEASONAL AFFECTIVE DISORDER MARKET SHARE BY END USER


Sources: The National Institute of Mental Health (NIMH), National Center for Biotechnology Information, U.S. National Library of Medicine, American Psychological Association, Directorate of Industries, annual report, white paper, company presentation


Regional Analysis of the Global Seasonal Affective Disorder Market             


The Americas hold the largest share in the global Seasonal affective disorder market. North America dominates the market in this region. Approximately 5% of the US population is suffering from seasonal depression Some other factors such as changing lifestyle plays an important role in market growth. South America market is also growing significantly, especially growth is higher in countries such as Brazil due to increasing awareness about various mental disorders.


The number of patients affected by seasonal affective disorder is increasing in Europe. The prevalence rate is higher in UK and Ireland. Approximately 2% population of Northern Europe is suffering from severe depression which results into seasonal affective disorder. Other European countries such as Germany and France are holding major market share in this region.


The prevalence of seasonal affective disorder in Asia Pacific region is about 0.9% which is lower as compare to North America and Europe. However, people are getting more aware about this disorder which is driving the seasonal affective disorder market growth. Some other factors such as developing health facilities, availability of treatments and products, changing lifestyle etc. are playing an important role in the growth of this market.


Due to low prevalence rate, less awareness of this disorder, and limited access to the healthcare facilities, Middle East & Africa seasonal affective disorder market is growing slower than the global average. The Middle Eastern countries are dominating this market due to developed healthcare infrastructure and increasing expenditure on health.


Research Methodology Research methodology Seasonal affective disorder Market


Sources: The National Institute of Mental Health (NIMH), National Center for Biotechnology Information, U.S. National Library of Medicine, American Psychological Association, Directorate of Industries, annual report, white paper, company presentation


Key Players in the Global Seasonal Affective Disorder Market                 


Some of the key players in this market: AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Henry Schein, Inc. (US), Pfizer Inc. (US), and others


Intended Audience



  • Seasonal Affective Disorder Diagnostic and Treatment Supplies Companies

  • Seasonal Affective Disorder Diagnostic and Treatment Supplies Providers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors



Frequently Asked Questions (FAQ) :


seasonal affective disorder market valuation would be USD 694.9 million by 2023.

seasonal affective disorder market CAGR would be 4.2% during the forecast period.

The diagnosis segment of the seasonal affective disorder market report includes psychological evaluation, physical exam, lab tests, and others.

The treatment types included in the seasonal affective disorder market report are medications, psychotherapy, counselling, light therapy (phototherapy), and others.

The Americas fetches the maximum seasonal affective disorder market revenue.

Table of Content

1. Report Prologue

2. Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

2.3 Market Structure

2.4. Market Segmentation

3. Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Mega Trends

4.5 Macroeconomic Indicators

5. Market Factor analysis

5.1 Value Chain Analysis

5.2 Porters Five Forces Analysis

5.3 Demand & Supply: Gap Analysis

5.4 Pricing analysis

5.5 Investment Opportunity Analysis

5.6 Merger and Acquisition Landscape

5.7 Upcoming Trends

6. Global Seasonal Affective Disorder Market by Type

6.1 Fall and winter SAD

6.2 Spring and summer SAD

6.3 Others

7. Global Seasonal Affective Disorder Market by Diagnosis

7.1 Physical exam

7.2 Lab tests

7.2.1 Complete Blood Count (CBC)

7.2.2 Thyroid Blood Tests

7.2.3 Others

7.3 Psychological evaluation

7.3.1 Intelligence tests

7.3.2 Personality tests

7.3.3 Attitude tests

7.3.4 Achievement tests

7.3.5 Achievement tests

7.3.6 Neuropsychological tests

7.3.7 Vocational tests

7.3.8 Direct observation tests

7.3.9 Others

7.4 Others

8. Global Seasonal Affective Disorder Market by Treatment

8.1 Light therapy (Phototherapy)

8.1.1 Bright light treatment

8.1.2 Dawn simulation

8.1.3 Others

8.2 Medications

8.2.1 Antidepressants

8.2.1.1 Reuptake Inhibitors (SSRIs)

8.2.1.1.1 Aroxetine (Paxil)

8.2.1.1.2 Sertraline (Zoloft)

8.2.1.1.3 Bupropion (Wellbutrin)

8.2.1.1.4 Venlafaxine (Effexor)

8.2.1.1.5 Others

8.2.2 Others

8.3 Psychotherapy

8.3.1 Art therapy

8.3.2 Attachment-based psychotherapy

8.3.3 Behavioral therapy

8.3.4 Body psychotherapy

8.3.5 Cognitive analytical therapy (CAT)

8.3.6 Existential psychotherapy

8.3.8 Gestalt therapy

8.3.8 Others

8.4 Counselling

8.5 Others

9. Global Seasonal Affective Disorder Market by End User

9.1 Hospital and clinics

9.2 Academic institutes

9.3 Medical Research centers

9.4 Others

10. Global Seasonal Affective Disorder Market by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 The US

10.2.1.2 Canada

10.2.2 Latin America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 China

10.4.2 India

10.4.3 Japan

10.4.4 South Korea

10.4.5 Australia

10.4.5 Rest of Asia Pacific

10.5 Middle East & Africa

10.5.1 UAE

10.5.2 Saudi Arabia

10.5.3 Egypt

10.5.4 Rest of the Middle East & Africa

11. Competitive Landscape

12. Company Profile

13. Conclusion

13.1 Key findings

13.1.1 From CEO’s viewpoint

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Seasonal affective disorder Market

14. Appendix